Free Trial

HC Wainwright's Rating of Neuphoria Therapeutics on 8/26/2025

On August 26, 2025, HC Wainwright updated its outlook on Neuphoria Therapeutics (NASDAQ:NEUP) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from HC Wainwright

DateCompanyAction
9/26/2025
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
Lower Price Target
9/26/2025
LightPath Technologies, Inc. stock logo
LPTH
LightPath Technologies
Boost Price Target
9/26/2025
DeFi Technologies Inc. stock logo
DEFT
DeFi Technologies
Reiterated Rating
9/26/2025
United States Antimony Co. stock logo
UAMY
United States Antimony
Boost Price Target
9/26/2025
Western Copper & Gold Corp stock logo
WRN
Western Copper & Gold
Boost Price Target
9/26/2025
Immunic, Inc. stock logo
IMUX
Immunic
Reiterated Rating
More Ratings From HC Wainwright